![]() |
Name |
(7S,10S)-7,10-epoxysydonic acid
|
Molecular Formula | C15H20O4 | |
IUPAC Name* |
3-hydroxy-4-[(2S,5S)-2-methyl-5-propan-2-yloxolan-2-yl]benzoic acid
|
|
SMILES |
CC(C)[C@@H]1CC[C@@](O1)(C)C2=C(C=C(C=C2)C(=O)O)O
|
|
InChI |
InChI=1S/C15H20O4/c1-9(2)13-6-7-15(3,19-13)11-5-4-10(14(17)18)8-12(11)16/h4-5,8-9,13,16H,6-7H2,1-3H3,(H,17,18)/t13-,15-/m0/s1
|
|
InChIKey |
NRHOCPZCIVKZEG-ZFWWWQNUSA-N
|
|
Synonyms |
(7S,10S)-7,10-epoxysydonic acid
|
|
CAS | NA | |
PubChem CID | 146684344 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 264.32 | ALogp: | 2.9 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 66.8 | Aromatic Rings: | 2 |
Heavy Atoms: | 19 | QED Weighted: | 0.868 |
Caco-2 Permeability: | -4.767 | MDCK Permeability: | 0.00001680 |
Pgp-inhibitor: | 0.007 | Pgp-substrate: | 0.008 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.002 |
30% Bioavailability (F30%): | 0.198 |
Blood-Brain-Barrier Penetration (BBB): | 0.103 | Plasma Protein Binding (PPB): | 75.22% |
Volume Distribution (VD): | 0.286 | Fu: | 22.20% |
CYP1A2-inhibitor: | 0.03 | CYP1A2-substrate: | 0.827 |
CYP2C19-inhibitor: | 0.026 | CYP2C19-substrate: | 0.091 |
CYP2C9-inhibitor: | 0.125 | CYP2C9-substrate: | 0.185 |
CYP2D6-inhibitor: | 0.01 | CYP2D6-substrate: | 0.115 |
CYP3A4-inhibitor: | 0.073 | CYP3A4-substrate: | 0.259 |
Clearance (CL): | 10.974 | Half-life (T1/2): | 0.813 |
hERG Blockers: | 0.046 | Human Hepatotoxicity (H-HT): | 0.515 |
Drug-inuced Liver Injury (DILI): | 0.915 | AMES Toxicity: | 0.157 |
Rat Oral Acute Toxicity: | 0.314 | Maximum Recommended Daily Dose: | 0.059 |
Skin Sensitization: | 0.295 | Carcinogencity: | 0.117 |
Eye Corrosion: | 0.018 | Eye Irritation: | 0.48 |
Respiratory Toxicity: | 0.729 |